Juvenile Dermatomyositis
Conditions
Keywords
juvenile dermatomyositis, baricitinib
Brief summary
The MYOCIT study aims to evaluate the efficacy and safety of baricitinib in association with corticosteroids in new-onset patients with juvenile dermatomyositis (JDM) in a phase II trial with the objective to obtain a better efficacy than the conventional combination methotrexate (MTX) and corticosteroids over the 24 week study period. Thus, the investigators hypothesize that baricitinib could be used as a first line treatment in all forms of DMJ, including the most severe one, with a good safety profile.
Detailed description
Juvenile dermatomyositis (JDM) is a rare and severe paediatric-onset idiopathic inflammatory myopathy, associated with significant morbidity and mortality. The combination of corticosteroids and methotrexate (MTX) is recommended in new-onset JDM according to one randomized trial. However, in this trial, treatment failures were reported in 13/46 (28%) patients and severe JDM, (cutaneous or gastrointestinal ulceration, interstitial pulmonary disease, cardiomyopathy) were not taken into account. These data emphasize the need for a more efficient first-line treatment. Considering: 1) the strong implication of type IFN-I in the pathophysiology of JDM 2) the report of the efficacy and safety of JAK inhibitors (JAKis) (baricitinb, tofacitinib) in about 50 refractory DM patients, and 9 JDM, a trial which evaluates the efficacy and safety of baricitinib in combination with corticosteroids in new-onset JDM is warranted.
Interventions
DRUGBaricitinib
Oral tablets (2 mg) will be used For children \> or = 6 years: 4 mg once a day (2 x 2 mg) during the 24 weeks-period study For children \< 6 years: 2 mg once a day during the 24 weeks -period study
BIOLOGICALpharmacokinetics study
additionnal blood sampling at week 4, 8, 12, and 24
BIOLOGICALdosage of cytokines
additionnal blood sampling at weeks 0, 4 and 24
BIOLOGICALtranscriptomic analysis
additionnal blood sampling at weeks 0, 4 and 24
BEHAVIORALParent version of the Child Health Questionnaire (CHQ)
Evaluate by parents at each visits
BEHAVIORALChildhood Health Assessment Questionnaire
Evaluate by parents at each visits
BIOLOGICALPregnancy test
Urine pregnancy test at V4 A dosage of bHCG with current biological analysis is done at each visit (except V4)
Sponsors
Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Patient aged 3-18 years with new-onset juvenile dermatomyositis, according to the ENMC 2018 dermatomyositis classification criteria * Muscle weakness at MMT and/or CMAS (MMT \< 74 and/or CMAS \< 45) * Seropositivity or vaccination for chickenpox * For patients of childbearing age (following menarche) : Negative βHCG and effective method of contraception (sexual abstinence, hormonal contraception, intrauterine device or hormone-releasing system, cap, diaphragm or sponge with spermicide, condom) until the 7 days after administration of the last dose of Baricitinib * Informed consent form signed by the patient or child' s parents Patient affiliated to a social security regime
Exclusion criteria
* Amyopathic dermatomyositis (without muscle weakness) * Inability to be treated by oral way or to take pills * Previous treatment with JAK inhibitor * Previous treatment of JDM with immunosuppressive drugs or biologics other than corticosteroids. Previous treatment with prednisone was allowed for no more than 1 month. * Previous history of cancer * Live vaccine within the 4 weeks before starting baricitinib therapy * Current, or recent (\< 4 weeks prior to baseline) of active infections according to investigator appreciation, but necessarily, including HBV, HCV, HIV, tuberculosis. * Positive blood CMV PCR * Creatinine clearance \< 40 ml/min * Lymphocytes \< 0,5x109 cell/L and Neutrophils \< 1x109 cell/L * Hemoglobin \< 8 g/dL * Symptomatic herpes herpes simplex infection within 12 weeks prior to inclusion * History of thrombosis or considered at high risk of venous thrombosis by the investigator * Presence of severe JDM-related involvements: cardiovascular (requiring vasopressive drug and/or intensive care unit), respiratory (requiring oxygen and/or intensive care unit), gastrointestinal (requiring abdominal surgery). * History of severe non-related JDM involvement: cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological or neuropsychiatric disorders or any other serious and/or instable illness that, in the opinion of the investigator, could constitute an unacceptable risk, when taking baricitinib. * Actual or in project of pregrancy and breast-feeding until the 7 days after administration of the last dose of Baricitinib * Patient on AME (state medical aid) * Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PRINTO 20 (Paediatric Rheumatology INternational Trials Organisation scale) | At week 24 | Achievement of the validated juvenile dermatomyositis PRINTO 20 level of improvement. PRINTO 20 level of improvement is defined as a 20% or greater improvement in three or more of the six variables of the juvenile dermatomyositis core set, with one or no variable worsening by more than 30% (muscle strength can not be the variable worsening) : 1. muscle strength, assessed with the Childhood Myositis Assessment Scale (CMAS), 2. physician's global assessment of the patient's disease activity (Physician's VAS) 3. global disease activity assessment through the Disease Activity Score (DAS) 4. functional ability through the Childhood Health Assessment Questionnaire (C-HAQ) 5. parent's global assessment of the child's overall wellbeing (Parent's VAS) 6. health-related quality of life, through the parent version of the Child Health Questionnaire (CHQ-Phs) A higher score is 100% and means a better outcome, a lower score is 0% and means a worse result. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PRINTO 20 Paediatric Rheumatology INternational Trials Organisation scale - level 20 | At week 4, 8, 12 and 16 | achievement of the validated juvenile dermatomyositis PRINTO 20 level ; reaching a minimum of 20 % a higher score is 100% and mean a better outcome a lower score is 0% and means a worse result |
| PRINTO 50 Paediatric Rheumatology INternational Trials Organisation scale - level 50 | At week 4, 8, 12 and 16 | achievement of the validated juvenile dermatomyositis PRINTO 50 level ; reaching a minimum of 50 % a higher score is 100% and mean a better outcome a lower score is 0% and means a worse result |
| PRINTO 70 Paediatric Rheumatology INternational Trials Organisation scale - level 70 | At week 4, 8, 12 and 16 | achievement of the validated juvenile dermatomyositis PRINTO 70 level ; reaching a minimum of 70 % a higher score is 100% and mean a better outcome a lower score is 0% and means a worse result |
| PRINTO 90 Paediatric Rheumatology INternational Trials Organisation scale - level 90 | At week 4, 8, 12 and 16 | achievement of the validated juvenile dermatomyositis PRINTO 90 level ; reaching a minimum of 90 % a higher score is 100% and mean a better outcome a lower score is 0% and means a worse result |
| Total Improvement Score (TIS) | At inclusion, weeks 4, 8, 12, 16 and 24 | Relative and absolute variations of TIS. The TIS is the sum of the improvement in each of the six core set measures of disease activits The minimum score is 0 (worse) and maximum score is 100 (better) A major response is defined by a score \> 70 A moderate response is defined by a score \> 45 A minimal response is defined by a score \> 30 |
| Clinically inactive disease | At weeks 4, 8, 12 and 24 | according to the PRINTO criteria |
| Cutaneous Dermatomyositis Disease Area and Severity Index (CDSAI) | At inclusion, weeks 4, 8, 12, 16 and 24 | assess skin activity and damage across multiple body regions in patients with dermatomyositis |
| Myositis Disease Activity Assessment VAS (MYOACT) | At inclusion, weeks 4, 8, 12, 16 and 24 | Assess Relative and absolute variations of extramuscular activity |
| interstitial lung disease | At inclusion and at week 24 | Assessed by improvement of at least 10% of FCV, PTC, and DLCO and/or improvement of Lung tomodensitomery according to a specific scale |
| Dose of corticosteroid | At week 24 | Dose tapering at 6 months |
| Pharmacokinetics study | At weeks 4, 8, 12, and 24 | Non-compartmental analysis of baricitinib |
| Pharmacokinetics (PK) study with area under the curve | At weeks 4, 8, 12, and 24 | Correlation between area under the curve AUC in ng.h/ml (PK parameter of baricitinib) and disease activity 's scores |
| Pharmacokinetics (PK) study with maximal concentration | At weeks 4, 8, 12, and 24 | Correlation between maximal concentration Cmax in ng/mL (PK parameter of baricitinib) and disease activity 's scores |
| Pharmacokinetics (PK) study with through concentration | At weeks 4, 8, 12, and 24 | Correlation between through concentration Ctrough, in ng/mL (PK parameter of baricitinib) and disease activity 's scores |
| dosage of cytokines | At inclusion, weeks 4 and 24 | Measurement of serum IFN -, IFN-γ, IL-1β, IL-4, Il-5, IL-6, IL-8, IL-10, IL-12p70, IL-22, TNF α |
| transcriptomic analysis | At inclusion, weeks 4 and 24 | Study of genes expression within 800 genes related to immunity |
| Biopsy | At inclusion, weeks 4 and 24 | Assessment of muscle biopsies according to the internationally validated score system |
Countries
France
Contacts
STUDY_DIRECTORCyril GITIAUX, Doctor
Assistance Publique - Hôpitaux de Paris
Outcome results
None listed